| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Natera, Inc.$269.95
-11.9 (-4.22%)
C 52Pipeline Score Diagnostics · Commercial
Market Cap
29.10 B
EPS
-1.64
P/E Ratio
-
Value Trade
308.34 M
SEC Financials
Q1 2026Dilution Risk
Revenue
696.64 M
R&D Expenses
210.70 M
Operating CF
40.17 M
Total Assets
2.61 B
Total Liabilities
840.38 M
Equity
1.77 B
D/E Ratio
12,345
2.82 %
Week
-2.03 %
1 Month
-6.09 %
3 Month
-9.69 %
6 Month
128.18 %
5 Year
819.41 %
All Time
Cash Data
Cash Position
1.09 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
969.80 K
52 Week Range
131.81 - 256.36
% held by Insiders
4.43 %
% held by Institutions
94.04 %
Enterprise Value
28.25 B
Total Shares
138.38 M
Short %
4.4 %
Float Shares
132.15 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Natera, Inc.
117Total events
3Upcoming
20Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 3
Event history 114
Jul 9, 2026
▲Other Regulator MilestoneSignateraEx-US Regulatory
Signatera receives IVDR Class C certification in EU
multiple cancerssource ↗
Jul 6, 2026
▲Oral PresentationSignateraPresentation
Oral presentation at 2026 ESMO GI Congress
resected colorectal liver metastasessource ↗
Jul 6, 2026
▲Full ResultsSignateraClinical Data
Publication in JAMA Oncology of Signatera MRD test predicting OS benefit from ACT in resected CRLM
resected colorectal liver metastasessource ↗
Jun 29, 2026
▲Partnership / LicenseCorporate
Natera and Aveta Biomics announce strategic partnership for global Phase 3 registrational trial of APG-157
head and neck cancersource ↗
Jun 25, 2026
▲Partnership / LicenseCorporate
Natera and Eledon announce strategic partnership for Prospera monitoring in planned Phase 3 kidney transplant trial
kidney transplantsource ↗
Jun 24, 2026
▲Other Regulator MilestoneSignateraEx-US Regulatory
Signatera receives regulatory approval in Japan for colorectal cancer
colorectal cancersource ↗
Jun 23, 2026
▲BLA SubmissionSignateraRegulatory Filing
NCCN recommends ctDNA-MRD testing using Signatera in bladder cancer guideline update
bladder cancersource ↗
Jun 18, 2026
May 29, 2026
▲Partnership / LicenseSignateraCorporate
Collaboration with Diakonos Oncology for Signatera in refractory melanoma
refractory melanomasource ↗
May 29, 2026
May 29, 2026
May 29, 2026
◆Oral PresentationSignateraPresentation
Multiple analyses from GALAXY study in CRC on serial Signatera testing and MRD-guided decision making
colorectal cancersource ↗
Drug Pipeline Intelligence
C52
Pipeline Score $1.5B
Pipeline ValueValuation Signal
9
Drugs Scored0.1x
rNPV / MCap Top 78%
Mid Cap (rank 202 of 912)
Percentile RankNatera, Inc. carries a moderate pipeline score (52/100), with $1.8B risk-adjusted pipeline value, led by Atezolizumab in Colon Adenocarcinoma (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Atezolizumab Small molecule | Muscle-invasive Bladder Cancer | Phase 3 | NCT04660344 | 42% | $871M | ACTIVE NOT_RECRUITING | 761 | AVERAGE | B (68) | Oct 1, 2026 | MODERATE_RISK | Mar 27, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
cema-cel | large B-cell lymphoma | — | 2026-04-14 | MRD clearance: 58.3%; ct DNA decrease: 97.7%; observation arm ct DNA change: 26.6% Read More | Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma Read More | |
cema-cel | large B-cell lymphoma | — | 2026-04-14 | MRD clearance: 58.3%; ct DNA decrease: 97.7%; observation arm ct DNA change: 26.6% Read More | Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma Read More | |
cema-cel | large B-cell lymphoma | — | 2026-04-14 | MRD clearance: 58.3%; ct DNA decrease: 97.7%; observation arm ct DNA change: 26.6% Read More | Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NTRA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NTRA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NTRA▼ -4.2%today
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
Natera, Inc. announced that its Signatera platform has achieved Class C certification under the European Union's In Vitro Diagnostic Regulation (IVDR). This certification is significant as it adheres to one of the most stringent regulatory frameworks for in vitro diagnostic devices. The approval is expected to bolster Natera's presence in the European market.
Read more →NTRASignatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
The article discusses the Signatera™ MRD test and its ability to predict overall survival benefits from chemotherapy in patients with resected metastatic colorectal cancer. However, the article lacks specific details and insights into the study or results. The information provided is minimal and does not elaborate on the implications of the findings.
Read more →NTRANatera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
Natera and Aveta Biomics have formed a strategic partnership to support a global Phase 3 registrational trial of APG-157, a treatment for head and neck cancer. This collaboration aims to enhance the development and potential approval of the therapy. Further details regarding the trial's design and objectives were not disclosed.
Read more →NTRANatera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
Natera and Eledon have formed a strategic partnership to utilize Prospera™ monitoring in a planned Phase 3 trial for kidney transplant patients. This collaboration aims to enhance patient monitoring and outcomes in transplantation. Further details about the trial and its objectives were not disclosed.
Read more →NTRA▲ +10.7%on this newsshared move
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
Signatera™, a product developed for colorectal cancer, has received regulatory approval in Japan. This approval marks a significant advancement in the treatment landscape for colorectal cancer patients. The introduction of Signatera™ is anticipated to provide enhanced therapeutic options and potentially improve patient outcomes in Japan.
Read more →NTRANCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
The NCCN has updated its guidelines to recommend ctDNA-MRD testing using Signatera™ technology for bladder cancer. This marks a significant advancement in the management of bladder cancer, reflecting the growing importance of personalized medicine. The recommendation aims to enhance patient outcomes through more accurate monitoring and treatment strategies.
Read more →NTRANatera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress
Natera is set to present its advancements in organ health at the American Transplant Congress. The company will showcase 21 presentations, highlighting its leadership in this field. This event underscores Natera's commitment to innovation and collaboration in organ health.
Read more →NTRANatera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
Natera has appointed Drs. Thomas Lynch and Eric Rubin to its Board of Directors. Both leaders bring extensive experience in oncology, which is expected to enhance Natera's strategic direction in the field. This move reflects Natera's commitment to strengthening its leadership team in oncology.
Read more →NTRANatera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
Natera has announced a collaboration with Diakonos Oncology to utilize its Signatera™ technology for patients with refractory melanoma. This partnership aims to enhance the treatment options available for this challenging cancer type. Further details on the specifics of the collaboration and its expected impact were not disclosed.
Read more →NTRA▲ +5.3%on this newsshared move
Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer
Natera has initiated the SIGNAL-ER 101 study, focusing on evaluating minimal residual disease (MRD)-guided therapy in breast cancer. The study aims to enroll patients to assess the efficacy of this innovative treatment approach. Further details about the study's design and objectives are not provided in the article.
Read more →NTRANatera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology
Natera has announced the launch of an enhanced version of its Panorama™ non-invasive prenatal testing (NIPT). This new offering is powered by innovative SNP-informed deep sequencing technology, which aims to improve the accuracy and effectiveness of prenatal testing. The enhancement is expected to provide better insights for expectant parents.
Read more →NTRANatera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
Natera is set to present 35 studies at the upcoming ASCO conference, showcasing its commitment to advancing clinical data in oncology. This presentation aims to reinforce Natera's leadership position in the oncology sector. The details of the studies and their implications for cancer treatment will be highlighted during the event.
Read more →NTRANatera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World
Natera has announced an expansion in Austin, Texas, which is set to create what is believed to be the largest sequencing facility in the world. This development is expected to significantly enhance the company's genetic testing capabilities. The expansion reflects Natera's commitment to growth and innovation in the biopharma sector.
Read more →NTRAEXPAND Trial of Natera’s Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled
Natera's EXPAND trial for its Fetal Focus™ single-gene non-invasive prenatal testing (NIPT) has successfully enrolled over 2,000 patients. This milestone indicates significant interest and participation in the trial, which aims to evaluate the effectiveness of the testing method. Further details on the trial's outcomes and implications are yet to be disclosed.
Read more →NTRANatera Reports First Quarter 2026 Financial Results
Natera has reported its financial results for the first quarter of 2026. The article provides insights into the company's performance during this period, though specific details regarding revenue, expenses, or strategic initiatives are not mentioned. The report is expected to influence investor sentiment and market positioning.
Read more →NTRA▲ +5.9%on this news
Natera to Report its First Quarter Results on May 7, 2026
Natera, Inc. will announce its first quarter results for 2026 on May 7, after market close. A conference call and webcast will follow at 1:30 p.m. PT. The company is recognized for its advancements in cell-free DNA and precision medicine, focusing on oncology and women's health.
Read more →NTRAProspera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT
Natera, Inc. announced the presentation of extensive evidence for its Prospera test at the 2026 ISHLT Annual Meeting. The test will be featured in 17 abstracts, including six oral presentations, showcasing its growing clinical utility in heart and lung transplantation. This highlights Natera's commitment to advancing precision medicine in transplantation.
Read more →NTRA▲ +6.3%on this news
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma
Natera highlighted positive interim results from Allogene Therapeutics' ALPHA3 trial, which evaluated the efficacy of cema-cel in large B-cell lymphoma patients with molecular residual disease. The trial showed that 58.3% of treated patients achieved MRD clearance, significantly outperforming the observation group. This study is the first MRD-guided randomized trial in LBCL, indicating potential for improved patient outcomes.
Read more →NTRAJudge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents
Natera, Inc. has received a favorable ruling from the U.S. District Court, which awarded a 30% ongoing royalty on post-injunction revenues from MRD-related product sales. This decision follows a previous jury ruling that upheld the validity of Natera's MRD patents. The company expressed satisfaction with the court's decision, highlighting the strength of its innovation in the field.
Read more →NTRA20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform
The article discusses Natera's presentation of 20 abstracts at the AACR conference, showcasing the scale, innovation, and clinical impact of its oncology platform. However, specific details about the abstracts or their findings are not provided. The focus remains on the company's efforts in oncology without delving into particular results or implications.
Read more →NTRA▲ +7%on this news
SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery
The article discusses the capabilities of SignateraTM MRD in identifying breast cancer patients who may not need surgery. However, specific details about the study or results are not provided. The implications of this technology on treatment decisions are significant, but further information is required to assess its impact fully.
Read more →NTRA▲ +5.2%on this news
Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers
Natera, Inc. announced two peer-reviewed studies demonstrating the clinical utility of its Signatera ctDNA assay in anal squamous cell carcinoma (ASCC) and locally advanced rectal cancer (LARC). The studies revealed that Signatera can effectively stratify recurrence risk and inform treatment decisions, showing strong correlations with patient outcomes. These findings highlight the assay's potential for personalized cancer management.
Read more →NTRASignatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation
Natera, Inc. presented new data on Signatera at the ASCO GU symposium, highlighting its effectiveness in monitoring treatment responses in muscle-invasive bladder cancer. The INDIBLADE and RETAIN trials demonstrated significant associations between Signatera status and patient outcomes, including bladder preservation. The findings suggest that Signatera could enhance clinical decision-making in managing genitourinary malignancies.
Read more →NTRANatera Reports Fourth Quarter and Full Year 2025 Financial Results
Natera, Inc. reported strong financial results for Q4 and full year 2025, with total revenues reaching $665.5 million in Q4, a 39.8% increase year-over-year. The company processed approximately 923,600 tests in Q4, contributing to a gross margin of 66.9%. Despite a net loss of $208.2 million for the year, Natera remains optimistic about its growth trajectory, projecting revenues of $2.62 billion to $2.70 billion for 2026.
Read more →NTRASuccessful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer
Natera, Inc. announced positive results from the Phase 2 SINERGY trial for recurrent or metastatic head and neck cancer. The trial utilized ctDNA monitoring to adapt treatment, leading to improved response rates and reduced toxicity. Approximately three-quarters of patients benefited from treatment de-escalation, indicating potential changes in standard care practices.
Read more →NTRANatera to Report its Fourth Quarter and Full Year Results on February 26, 2026
Natera, Inc. has announced it will report its fourth quarter and full year results for 2025 on February 26, 2026. The results will be released after market close, followed by a conference call and webcast at 1:30 p.m. PT. The company is recognized for its leadership in cell-free DNA and precision medicine.
Read more →NTRANatera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes
Natera has launched the EDEN study, a large prospective trial aimed at evaluating its non-invasive prenatal screening test for early risk assessment of preeclampsia and other serious pregnancy complications. The study will enroll up to 7,500 pregnant participants in the U.S. to assess risks associated with preeclampsia and adverse outcomes. This initiative seeks to enhance early detection and improve maternal care.
Read more →NTRANatera Submits Signatera™ CDx PMA to FDA
Natera, Inc. has submitted a premarket approval application to the FDA for its Signatera CDx test, aimed at detecting molecular residual disease in muscle-invasive bladder cancer patients. This application is backed by positive results from the IMvigor011 phase 3 clinical trial, which indicated significant improvements in disease-free and overall survival for patients treated with atezolizumab. If approved, Signatera CDx could become a pivotal tool in guiding treatment decisions for bladder cancer.
Read more →NTRANatera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
Natera has completed enrollment in the ACES-EMB trial, the first randomized-controlled study comparing dd-cfDNA surveillance to routine biopsies in heart transplantation. The trial aims to evaluate the effectiveness of the Prospera Heart test in monitoring organ rejection non-invasively. Positive outcomes could shift the standard of care away from invasive procedures, benefiting thousands of patients annually.
Read more →NTRAProspera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care
A new clinical trial published in Transplantation Direct shows that Prospera-guided monitoring significantly reduces the need for invasive biopsies in lung transplant patients. Conducted by The Ohio State University Wexner Medical Center, the study found that over 75% of low-risk patients could safely avoid routine biopsies at nine months post-transplant. This approach enhances patient care while maintaining safety and outcomes.
Read more →NTRANatera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
Natera, Inc. announced the publication of a validation study for its Latitude tissue-free MRD test in colorectal cancer, demonstrating high clinical performance. The study analyzed data from 195 patients and supports submission to CMS for the Molecular Diagnostics Services Program. Natera aims to expand the test's application to additional cancer types by 2026.
Read more →NTRANatera’s Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting
Natera, Inc. announced that its EXPAND clinical trial will be featured in an oral plenary presentation at the upcoming Society of Maternal Fetal Medicine (SMFM) meeting. The trial focuses on the Fetal Focus technology, which assesses inherited disease-causing variants in fetuses. The presentation will showcase the trial's key results and robust design, underscoring Natera's commitment to women's health and high-quality clinical evidence.
Read more →NTRANatera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling
Natera, Inc. has announced a breakthrough in molecular residual disease (MRD)-based risk stratification, utilizing a multi-modal AI model. This model integrates ctDNA, clinical data, and digital pathology to enhance the Signatera MRD assessment. The innovation aims to improve personalized cancer treatment and is backed by extensive patient data. Results are anticipated to be shared at an upcoming conference.
Read more →NTRANatera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera Growth 2025 revenues are expected to increase by approximately 35% compared to 2024, which is approximately $40 mil
Natera, Inc. has announced strong preliminary financial results for the fourth quarter and fiscal year 2025, projecting a revenue increase of approximately 35% from the previous year. The growth is attributed to record performance of their Signatera product. Despite these optimistic projections, the results are preliminary and subject to audit, with the company acknowledging ongoing financial challenges and uncertainties in achieving future goals. Detailed results will be provided during their earnings call in February 2026.
Read more →NTRAOctave Bioscience Expands Leadership Team with Appointment of Kirk Stockwood Senior Vice President, Commercial
Octave Bioscience has appointed Kirk Stockwood as Senior Vice President, Commercial, to lead its commercial strategy. With over 20 years of experience in specialty diagnostics, Stockwood aims to expand Octave's precision neurology platform. His previous roles include significant contributions to Natera and Quanterix, indicating a strong potential for growth at Octave.
Read more →NTRANatera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI
Natera, Inc. announced updated analyses from the ALTAIR clinical trial, which demonstrated a statistically significant disease-free survival (DFS) benefit for patients treated with Trifluridine/Tipiracil compared to placebo. This new data will be presented at the ASCO GI symposium in January 2026. The findings mark a significant improvement over earlier results that did not achieve statistical significance.
Read more →NTRANatera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology
Natera has launched its expanded 21-gene Fetal Focus single-gene non-invasive prenatal test (sgNIPT), demonstrating high accuracy in detecting inherited conditions. The test achieved 96% sensitivity and 98% specificity in the EXPAND clinical trial, validating its effectiveness across diverse populations. This advancement aims to provide clinicians with essential information for managing pregnancies with potential genetic risks.
Read more →NTRANatera to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Natera, Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The company's management will present and host a Q&A session for investors. Natera is recognized for its advancements in cell-free DNA and precision medicine, aiming to integrate genetic testing into standard healthcare practices.
Read more →NTRANatera Acquires Foresight Diagnostics
Natera, a leader in precision medicine, has acquired Foresight Diagnostics to enhance its capabilities in molecular residual disease (MRD) detection, particularly in lymphoma. This acquisition combines Natera's operational infrastructure with Foresight's advanced phased variant technology, potentially accelerating MRD adoption across solid tumors. The all-stock transaction is valued at $275 million upfront, plus $175 million contingent on performance milestones. Natera and Foresight will showcase their advancements at the American Society of Hematology Annual Meeting, further establishing their leadership in the field.
Read more →NTRANatera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium
Natera, Inc. announced the presentation of twelve abstracts at the 2025 San Antonio Breast Cancer Symposium, featuring data from over 50,000 patients. The studies highlight the effectiveness of Signatera in detecting recurrence and optimizing treatment across various breast cancer subtypes. Key findings include a 100% sensitivity and specificity in detecting recurrence in a cohort of breast cancer patients.
Read more →NTRANatera Reports Third Quarter 2025 Financial Results
Natera, Inc. has released its financial results for the third quarter of 2025, showcasing significant revenue growth attributed to an increase in clinical volume and an improved average selling price. The company reported total revenues of $592.2 million, a 34.7% increase from the previous year. However, despite these gains, Natera experienced a net loss of $87.5 million. The report highlighted advancements in their clinical offerings, including the largest increase in quarterly MRD units to date, alongside new results for cancer detection and a broader prenatal testing panel.
Read more →NTRANatera Reports Second Quarter 2025 Financial Results
Natera, Inc. reported its financial results for the second quarter of 2025, demonstrating a strong revenue increase of 32.2% year-over-year, totaling $546.6 million. The company also achieved a gross margin improvement to 63.4% and processed over 853,100 tests, including a notable 50.6% rise in oncology tests. Despite these positive indicators, Natera recorded a higher net loss of $100.9 million attributed to increased operating expenses and legal accruals. The company raised its annual revenue outlook by $80 million, reflecting its confidence in ongoing growth.
Read more →NTRANatera Reports First Quarter 2025 Financial Results
Natera, Inc. reported its financial results for the first quarter of 2025, showcasing substantial growth with total revenues reaching $501.8 million, a 36.5% increase from the prior year. Test processing saw a notable rise, with 855,100 tests conducted, highlighting operational advancements. Despite these positive financial metrics, the company reported a net loss of $66.9 million and increased total operating expenses driven by headcount and legal costs. Natera continues to focus on expanding its product offerings and improving its market position in genetic testing.
Read more →NTRANatera Reports Fourth Quarter and Full Year 2024 Financial Results
Natera, Inc. reported impressive financial results for Q4 and full year 2024, achieving a substantial revenue increase driven by higher product volume and pricing. Total revenues reached $476.1 million in Q4 2024, up 53% from the previous year. However, the company saw a notable rise in operating expenses, raising concerns about cost management. Natera projects continued revenue growth for 2025, while still facing significant net losses.
Read more →NTRANatera Announces Preliminary Fourth Quarter and Full-Year Results for 2024 2024 revenues are expected to increase by approximately 56% compared to 2023, which is approximately $53 million above top end of financial outlo
Natera, Inc. announced its preliminary results for the fourth quarter and full year of 2024, anticipating a 56% revenue increase compared to the previous year, exceeding the upper limit of its financial outlook by $53 million. The company plans to present these results at the J.P. Morgan Healthcare Conference. Despite this positive projection, Natera cautioned that the results are preliminary and unaudited, and acknowledged ongoing net losses and potential fluctuations in quarterly results. The complete financial results will be disclosed during an earnings call in February 2025.
Read more →NTRANatera Reports Third Quarter 2024 Financial Results
Natera, Inc. reported strong financial results for the third quarter of 2024, showcasing a 63.9% increase in revenue year-over-year, largely driven by a surge in product revenues. The CEO emphasized the company's commitment to patient care and noted significant growth in test volumes, which contributed to a gross margin increase to 61.8%. Although the company reported a net loss, the overall positive trends suggest a solid performance amidst ongoing challenges in the market. The outlook for 2024 remains cautiously optimistic as Natera continues to navigate operational hurdles.
Read more →NTRA▲ +7.3%on this news· ran to +19% by day 3
Natera Reports Second Quarter 2024 Financial Results
Natera, Inc. reported significant financial improvements for the second quarter of 2024, with total revenues reaching $413.4 million, up 58.1% from the same period the previous year. The company also achieved a gross profit of $243.2 million, resulting in a gross margin of 58.8%. Despite reporting a net loss of $37.5 million, this figure represented an improvement compared to $110.8 million in the previous year. Natera projects continued growth, with expected total revenues for 2024 between $1.49 billion and $1.52 billion.
Read more →NTRANatera Reports First Quarter 2024 Financial Results
Natera, Inc. reported strong financial results for the first quarter of 2024, with total revenues rising by 52.1% year-over-year to $367.7 million. The increase was primarily driven by product revenue growth. The company achieved cash flow breakeven sooner than anticipated and launched a new product in women's health. Despite a reported net loss of $67.6 million, Natera showed significant improvement in gross margins, reaching 56.7%. The company continues to focus on expanding its offerings in oncology, women's health, and organ health.
Read more →NTRANatera Reports Fourth Quarter and Full Year 2023 Financial Results
Natera, Inc. reported its financial results for the fourth quarter and full year of 2023, showcasing significant growth in total revenues and an improvement in gross margins. The company's total revenues reached $1,082.6 million for the year, a 32% increase from 2022, while gross margins rose to 51.4% in Q4 2023. Despite these positive trends, Natera incurred a net loss of $78 million in Q4 and reported rising operating expenses. Looking ahead, the company forecasts revenues of $1.32 billion to $1.35 billion for 2024.
Read more →NTRANatera Acquires Reproductive Health Assets from Invitae
Natera, Inc. has acquired certain reproductive health assets from Invitae for $10 million, along with potential milestone payments of up to $42.5 million. This acquisition will allow Natera to transition Invitae's customers for non-invasive prenatal and carrier screening. Natera's CEO expressed commitment to providing high-quality service to new patients and providers. Despite the positive outlook, the company acknowledges potential risks and uncertainties linked to such strategic transactions.
Read more →NTRANatera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues 2023 revenues are expected to be approximately $20 million above top end of guidance
Natera, Inc. has announced that its preliminary revenue results for the fourth quarter and full year of 2023 are expected to exceed previous guidance by approximately $20 million. The company, recognized as a leader in cell-free DNA testing, will release detailed financial results during an earnings call in February 2024. The preliminary figures are based on initial management reviews and are subject to adjustments and auditing, meaning final results may vary significantly.
Read more →NTRA▼ -5.3%on this news
Natera Reports Third Quarter 2023 Financial Results
Natera, Inc. reported a strong third quarter for 2023, with revenue reaching $268.3 million, representing a 27.4% increase compared to the previous year. The company also noted an increase in test volumes processed, which contributed to its growth. Despite a net loss of $109 million, the company achieved an operational reduction in cash burn and revised its annual revenue guidance upwards. The strategic focus remains on advancing its clinical studies and enhancing product adoption in cell-free DNA testing.
Read more →NTRANatera Launches Proposed Follow-On Offering
Natera, Inc. announced a proposed follow-on public offering of $250 million in common stock, with an additional $37.5 million offered to underwriters. This initiative aims to bolster the company’s capacity in the cell-free DNA testing market, particularly within oncology and women's health. The offering is contingent on market conditions and is part of Natera's ongoing efforts to enhance personalized genetic testing. Forward-looking statements indicate potential risks tied to market acceptance and changes that could affect the offering's final structure.
Read more →NTRANatera Reports Second Quarter 2023 Financial Results
Natera, Inc. reported robust financial results for the second quarter of 2023, achieving a 31.9% increase in total revenues compared to the same period last year. The company processed over 617,200 tests, reflecting a growth of 23.5% in test volumes. As a result of this strong performance, Natera raised its annual revenue guidance and indicated improvements in gross margin. Despite ongoing losses, the company's clinical pipeline, particularly in oncology, positions it favorably for future advancements.
Read more →NTRANatera Reports First Quarter 2023 Financial Results
Natera, Inc. reported significant financial growth in its first quarter of 2023, with a total revenue of $241.8 million, marking a 24.5% increase from the previous year. The company processed approximately 626,200 tests, including a notable increase in oncology tests. Despite the positive revenue growth and new Medicare coverage for Prospera, Natera faced challenges with decreased gross margins and a continuing net loss of $136.9 million. The company has raised its revenue guidance for the year, demonstrating confidence in its ongoing expansion and market position.
Read more →NTRANatera Reports Fourth Quarter and Full Year 2022 Financial Results
Natera, Inc. reported its fourth quarter and full year 2022 financial results, showing a 31.1% revenue increase year-over-year. The company processed a record number of tests, reflecting a strong demand for its cell-free DNA testing services. Despite the revenue growth, Natera faced a net loss of $547.8 million for the year. Looking ahead, the company provided optimistic guidance for 2023, expecting revenues between $980 million and $1 billion.
Read more →NTRANatera Reports Third Quarter 2022 Financial Results
Natera Reports Third Quarter 2022 November 8, 2022 /PRNewswire/ - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2022. Recent Strategic and Financial Highlights Generated tota
Read more →NTRANatera Reports Second Quarter 2022 Financial Results
Natera Reports Second Quarter 2022 Financial Results Texas, August 4, 2022 /PRNewswire/ - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent busine
Read more →NTRA▼ -7.4%on this news· ran to -18% by day 3
Natera Reports First Quarter 2022 Financial Results
Natera Reports First Quarter 2022 Financial Results Texas, May 5, 2022 /PRNewswire/ - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2022 and provided an update on recent business pr
Read more →NTRA▼ -7.9%on this news· ran to -22% by day 1
Natera Executives and Board to Take Pay in Stock Instead of Cash Leadership, Board to Exchange Cash Compensation for Shares
Natera Executives and Board to Take Pay in Stock Leadership, Board to Exchange Cash Compensation AUSTIN, Texas, March 14, 2022 - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced that its executive leaders and board of directors have unanimously
Read more →NTRA▲ +7.4%on this news
Natera Reports Fourth Quarter and Full Year 2021 Financial Results
Natera Reports Fourth Quarter and Full Year 2021 Financial Results AUSTIN, Texas, February 24, 2022 /PRNewswire/ - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the fourth quarter and year ended December 31, 2021 a
Read more →NTRANatera Reports Third Quarter 2021 Financial Results
Natera Reports Third Quarter 2021 Financial AUSTIN, Texas, November 4, 2021 /PRNewswire/ - Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing, today reported financial results for the third quarter ended September 30, 2021 and provided an update on recent bu
Read more →Competitive Position
How NTRA ranks across every disease it competes inCompetitive Position is a premium feature
See how NTRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial